News
KalVista bags FDA approval for delayed oral HAE drug
KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market.
News
J&J bids to extend prostate cancer uses for Akeega
J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.
Sales & Marketing
Closed & Collaborative H1 2025: Mergers, acquisitions, colla...
The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and biotechnology sectors.
News
UK pharma has concerns about the new NHS 10-year plan
The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
News
AZ claims EU okay for Imfinzi in bladder cancer
AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
